Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
VIVUS, Inc. |
---|---|
Information provided by: | VIVUS, Inc. |
ClinicalTrials.gov Identifier: | NCT00914511 |
The purposes of this study are to:
Condition | Intervention | Phase |
---|---|---|
Avanfil ADME Semen Exposure Sperm Function |
Drug: avanafil 200mg |
Phase I |
Study Type: | Interventional |
Study Design: | Basic Science, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study |
Official Title: | A Phase I, Single-Center, Open-Label, Non-Randomized, Two-Cohort Study to Assess the Effect of Age on the Pharmacokinetics of Avanafil And To Determine Avanafil Semen Exposure and the Acute Effect of Avanafil on Sperm Function in Healthy Young Male Subjects Following a Single Oral Dose of 200 mg |
Estimated Enrollment: | 32 |
Study Start Date: | May 2009 |
Estimated Study Completion Date: | October 2009 |
Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Healthy young males: Experimental
Healthy young males age 18-45, inclusive
|
Drug: avanafil 200mg
single dose tablet of 200mg avanafil
|
Elderly males: Experimental
Elderly males 65 years of age and older
|
Drug: avanafil 200mg
single tablet dose of 200mg avanafil
|
This single-center, open-label, non-randomized, two-cohort, single-dose pharmacokinetic study will be conducted at a single site in the United States, in which at least 18 young (18-45 years, inclusive) male subjects in Cohort A and 14 elderly (65 years or older) males in Cohort B will be enrolled and dosed to achieve a total of at least 14 completed young subjects and 12 elderly subjects. Seminal fluid and plasma will be collected from Cohort A, whereas only plasma samples will be collected from Cohort B.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Major exclusion criteria for all subjects include:
Contact: Daniel Zamfir, BS | 602-437-0097 ext 67188 | daniel.zamfir@mdsinc.com |
United States, Arizona | |
MDS Pharma Services | Recruiting |
Tempe, Arizona, United States, 85283 | |
Principal Investigator: Dennis Swearingen, M.D. |
Study Director: | Shiyin Yee, PhD | VIVUS, Inc. |
Responsible Party: | Vivus, Inc. ( Wesley Day, VP Clinical Development ) |
Study ID Numbers: | TA-014 |
Study First Received: | June 3, 2009 |
Last Updated: | June 4, 2009 |
ClinicalTrials.gov Identifier: | NCT00914511 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Semen Sperm Avanafil Pharmacokinetics Elderly |
Healthy Spastic Paraplegia Epilepsy Mental Retardation |